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Identifying signaling networks in melanoma tumors that promote the
uncontrolled growth of BRAF mutant melanocytes
H Xiao1, C Chen2, J Shiu2, R Ruiz1, MG Caldwell1, AD Lander1 and AK Ganesan2 1 Center for
Complex Biological Sciences, University of California Irvine, Irvine, California, United States
and 2 Department of Dermatology, University of California Irvine, Irvine, California, United
States
Melanocytic nevi (AKA moles) are benign proliferations of melanocytes induced by the same
BRAF mutation that initiates melanoma. BRAF mutant melanocytes in nevi eventually undergo growth arrest whereas melanomas do not, raising the question that how do melanoma
tumors escape growth arrest and continue to progress uncontrolledly? In answering this
question, we recently determined that simply crossing the BRAF mutation from black mice
into an isogenic albino background was sufficient to induce melanoma formation. BRAF
mutant albino tumors did not have any new mutations, indicating that factors that influence
tumor formation in these models must be epigenetic. We next sought to define signaling
networks present in BRAF mutant albino melanomas that are absent in BRAF mutant black
nevi. Single cell RNA sequencing analysis of melanoma tumors identified discrete macrophage and fibroblast populations that were observed in BRAF induced melanomas but not in
BRAF induced nevi. Specifically, we identified a distinct population of melanocytes with a
Schwann cell-like gene expression signature (termed S cells) that have a similar gene
expression pattern to the neural crest stem cells that are thought to regulate BRAF inhibitor
resistance. These S cells were observed in both BRAF and BRAF PTEN melanoma tumors as
well as human melanomas. Intriguingly, the S cells present in nevi had a different gene
expression pattern than the S cells observed adjacent to melanomas. Taken together, these
results indicates that discrete cells in the melanocytic lineage promote tumorigenesis by
secreting growth promoting signals that allow BRAF mutant melanocytes to overcome growth
arrest.

Current treatment options for patients with unresectable cutaneous melanoma
S Shimon1, D Sharad2, E Schlam3 and S Gonzalez-Escola2 1 Nova Southeastern University
College of Allopathic Medicine, Davie, Florida, United States, 2 Westside Regional Medical
Center, Plantation, Florida, United States and 3 University of Miami School of Medicine,
Miami, Florida, United States
Cutaneous Melanoma (CM) remains the leading cause of skin-related mortality in the U.S.
The U.S. Surveillance, Epidemiology and End Results database reports 5.6% of all new cancer
cases in 2021 attributed to CM, with incidences rising annually since 2009. Several subtypes
of CM are thought to arise from early driver mutations in BRAF, RAS, and NF1 genes resulting
in unopposed activation of MAPK and PI3K signaling pathways, unregulated growth and
malignant transformation of melanocytes. Due to the metastatic potential of CM, emphasis on
systemic treatment has been an area of interest when surgical resection is insufficient for
curative prognosis. Our case involves a 65 year old patient who presents for management of a
8.5mm tumor with ulceration and multiple associated subcutaneous satellite lesions on his
left scapula. At his most recent follow up, he has experienced a 5kg weight loss, fatigue,
shortness of breath, and non-tender axillary lymphadenopathy. Excisional biopsy revealed
nodular-variant malignant melanoma, and immunoperoxidase studies were positive for
SOX10 and Melan-A, confirming the diagnosis. CT of the chest showed enlarged bilateral
axillary lymph nodes with areas of necrosis, as well as punctate bilateral pulmonary nodules,
consistent with metastasis. Based on the American Joint Committee of Cancer classification,
our patient has T4N2M1b consistent with stage IV melanoma and a 53% one year prognostic
survival. Due to his unresectable tumor, systemic treatment using immune checkpoint inhibitors or targeted therapy is indicated. As of 2011, the FDA approved immunomodulator
therapy, such as CTLA4 inhibitors and PD1 inhibitors, which promote CD8+ T cell death. Of
these, nivolumab, a PD1 inhibitor, has been shown to have increased response rates (43% vs
19%), and 3 year survival (52% vs 37%) than CTLA-4 inhibitors, such as ipilimumab. Due to
these benefits and lower side effect profile, we chose nivolumab as the drug of choice for our
patient.
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Modulation of the aryl hydrocarbon receptor by adipose tissue: Implications
for skin carcinogenesis
S Shareef1, J Veenstra2 and JJ Bernard3,4 1 Michigan State University College of Human
Medicine, East Lansing, Michigan, United States, 2 Department of Dermatology, Henry Ford
Health System, Detroit, Michigan, United States, 3 Department of Dermatology, Department
of Medicine, Michigan State University College of Human Medicine, East Lansing, Michigan,
United States and 4 Michigan State University Department of Pharmacology and Toxicology,
East Lansing, Michigan, United States
The aryl hydrocarbon receptor(AhR) is a ligand-activated transcription factor that responds to
chemical carcinogens. An endogenous AhR agonist, 6-Formylindolo[3,2-b]carbazole, is produced
following ultraviolet light(UV) absorption by tryptophan. Epidemiological studies show a correlation between exposure to AhR agonists and non melanoma skin cancer(NMSC). As an example,
AhR activation promotes metabolism of pro-carcinogens to carcinogens such as the metabolism of
benzo(a)pyrene to benzo[a]pyrene diol epoxide(BPDE). There are differing epidemiological
studies which explain the relationship between obesity and NMSC—some demonstrate a positive
association while others demonstrate a negative association. However, evidence supporting an
inverse correlation is relatively weak and heavily confounded by UV exposure among body mass
index groups. Our objective was to determine the role of AhR in adipose tissue-stimulated malignant transformation. RNA-seq analysis demonstrated that secretions from adipocytes induced
AhR-regulated phase I metabolizing enzymes in a non-tumorigenic, mouse epidermal cell line, JB6
P+, including CYP1A1 which metabolizes B[a]P to BPDE. Phase II detoxifying enzymes remained
unchanged or reduced suggesting xenobiotic metabolism by adipocyte secretions. Together, B[a]P
and adipocyte secretions induce malignant transformation, assessed by the JB6 P+ soft agar clonogenic assay. Primary human keratinocytes, cultured with adipocyte-conditioned medium for 24
hours, demonstrated elevated AhR protein levels and induction in CYP1A1 and CYP1B1
mRNA(3.6 and 10.2-fold)compared to the media control cells. Understanding how adipocytes
modulate AhR activity in skin with or without environmental AhR ligands will lead to new therapeutic strategies to prevent epidermal cell transformation.

In vivo tracking of clonal dynamics shows three phases of UV-induced skin
carcinogenesis
S Avdieiev1,2, L Tordesillas3, O Chavez Chiang3, Z Chen4, L Silva Simoes2, Y Chen4,
N Andor2, R Gatenby1,2, E Flores5, J Brown1,2 and KY Tsai1,3 1 Cancer Biology and Evolution
Program, Moffitt Cancer Center, Tampa, Florida, United States, 2 Integrated Mathematical
Oncology, Moffitt Cancer Center, Tampa, Florida, United States, 3 Tumor Biology Department, Moffitt Cancer Center, Tampa, Florida, United States, 4 Department of Biostatistics and
Bioinformatics, Moffitt Cancer Center, Tampa, Florida, United States and 5 Department of
Molecular Oncology, Moffitt Cancer Center, Tampa, Florida, United States
We hypothesize that skin cancer emerges from a combination of mutations and tissue disruption. We characterize clonal dynamics and transcriptional signatures during skin carcinogenesis using lineage tracing. For 3 months, we UV-irradiated fluorophore expressing K14Cre-ERT2
Confetti mice. Clone volumes were computed from 3-D digitized confocal z-stacks. scRNAseq
was used to compare UV-exposed (EXP) epidermis, non-exposed (NON), and tumors. Over 6
months from the UV initiation, we generated 914 serial images of the EXP/NON skin. We
analyzed 16,135 clones from the EXPand 21,506 clones from the NON skin. Median clone size
did not differ between UV treatments and did not change with time. However, the mean size of
EXP clones were 50% larger than NON ones, with a >6-fold increase in variance. The number of
large EXP clones increased dramatically by months 3-4, plateauing at months 5-6. scRNAseq of
EXP/NON epidermis and tumors revealed 16 clusters corresponding to different differentiation
states. We observed dynamic changes to the clusters when progressing from normal to chronically exposed skin, and then to tumors. Development of large clones preceded high penetrance
mutations. EXP clusters were associated with expression of cystatins (Scfa 3, BC100530), and
alarmins/proliferative keratins (Krt16, Krt6a). Flr-expressing keratinocytes from large EXP clones
exhibited altered keratinocyte differentiation, inflammation, and upregulation of metabolic
regulators. These results show an initial disruption of tissue (2-3 months) permitting the emergence of unusually large clones (phase 1), followed by inter-clonal competition and mutational
buildup (phase 2) and the emergence of lesions (phase 3).
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Defining the immune response in basal cell carcinoma spontaneous regression
KN Wong1,2,3 and S Atwood1,2,3 1 University of California Irvine Department of Developmental and Cell Biology, Irvine, California, United States, 2 Center for Multiscale Cell Fate
Research, Irvine, California, United States and 3 University of California Irvine Cancer
Research Institute, Irvine, California, United States
In the US, more people are diagnosed with basal cell carcinoma (BCC) than any other cancer,
but treatment of advanced tumors is frequently complicated by drug resistance. Interestingly,
20-29% of human BCC tumors are reported to shrink spontaneously in the absence of
treatment through an unknown mechanism. With case studies suggesting a role for immune
activation in this tumor regression, we hypothesize that T cells are recruited to growing BCCs
to promote spontaneous tumor shrinkage. The inducible Gli1CreERT2; Ptch fl/fl transgenic
BCC mouse model shows microtumor growth in the skin followed by significant reduction
(p<0.001) in tumor area after 10 weeks. Using this model of regression in the absence of
treatment, we assess the role of immune system interactions in promoting this mechanism and
as a potential therapeutic target. Analysis of immune infiltration, bulk and single-cell RNAsequencing of tumor-bearing skin shows evidence of an inflammatory neutrophil response
during tumor growth followed by a transient cytotoxic T cell response. By assessing T cell
necessity and the sufficiency of upregulated cytokines in inducing anti-tumor responses, we
aim to define the immune response against BCC tumors and determine the role of effector T
cells in regulating regression. This study will identify the cell populations, pathways, and
interactions critical to the tumor regression mechanism and BCC pathogenesis. This will
provide candidate therapeutic targets to enhance tumor regression, thus facilitating the
development of alternative therapies to treat advanced BCCs.
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mRNA methylation in skin tumorigenesis and therapeutic resistance
Y Cui1, S Yang1, J Wei2, CR Shea1, W Zhong1, F Wang1, P Shah1, M Kibriya1, X Cui2,
H Ahsan1, C He2 and Y He1 1 University of Chicago Division of the Biological Sciences,
Chicago, Illinois, United States and 2 University of Chicago Division of the Physical
Sciences, Chicago, Illinois, United States
Analogous to DNA and histone modifications, RNA molecules are chemically modified, the
study of which gives rise to the field called epitranscriptomics. Among these modifications,
N6-methyladenosine (m6A) RNA methylation is the most abundant internal modification in
messenger RNA (mRNA) and non-coding RNA in eukaryotic cells, which regulates RNA
metabolism, including RNA decay, translation and nuclear processing. However, the regulatory and functional role of m6A RNA methylation in skin cancer remain poorly understood.
Recently we demonstrated that the m6A mRNA demethylase FTO promotes tumorigenesis
and resistance to immunotherapy in melanoma. In addition, using skin-specific conditional
knockout mouse models, in combination with in vitro cellular models, recently we have
demonstrated a pivotal role of m6A RNA methylation in skin cancer development. FTO as an
N6-methyladenosine (m6A) RNA demethylase is degraded by selective autophagy, which is
impaired by low-level arsenic exposure to promote tumorigenesis. We found that in arsenicassociated human skin lesions, FTO is up-regulated, while m6A RNA methylation is downregulated. In keratinocytes, chronic relevant low-level arsenic exposure up-regulated FTO,
down-regulated m6A RNA methylation, and induced malignant transformation and tumorigenesis. Moreover, in mice, epidermis-specific FTO deletion prevented skin tumorigenesis
induced by arsenic and UVB irradiation. Targeting FTO genetically or pharmacologically
inhibits the tumorigenicity of arsenic-transformed tumor cells. We identified NEDD4L as the
m6A-modified gene target of FTO. Finally, arsenic stabilizes FTO protein through inhibiting
p62-mediated selective autophagy. Our study reveals FTO-mediated dysregulation of mRNA
m6A methylation as an epitranscriptomic mechanism to promote arsenic tumorigenicity and
may open up new opportunities to reduce skin cancer burden.

